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Abstract: Peroxidasin (PXDN) is a unique peroxidase containing extracellular matrix motifs
and stabilizes collagen IV networks by forming sulfilimine crosslinks. PXDN gene knockout
in Caenorhabditis elegans (C. elegans) and Drosophila results in the demise at the embryonic and
larval stages. PXDN mutations lead to severe eye disorders, including microphthalmia, cataract,
glaucoma, and anterior segment dysgenesis in humans and mice. To investigate how PXDN loss of
function affects organ development, we generated Pxdn knockout mice by deletion of exon 1 and
its 5′ upstream sequences of the Pxdn gene using the CRISPR/Cas9 system. Loss of both PXDN
expression and collagen IV sulfilimine cross-links was detected only in the homozygous mice,
which showed completely or almost closed eyelids with small eyes, having no apparent external
morphological defects in other organs. In histological analysis of eye tissues, the homozygous
mice had extreme defects in eye development, including no eyeballs or drastically disorganized eye
structures, whereas the heterozygous mice showed normal eye structure. Visual function tests also
revealed no obvious functional abnormalities in the eyes between heterozygous mice and wild-type
mice. Thus, these results suggest that PXDN activity is essential in eye development, and also indicate
that a single allele of Pxdn gene is sufficient for eye-structure formation and normal visual function.
Keywords: peroxidasin; knockout mice; anophthalmia; microphthalmia; eye development;
CRISPR/Cas9
1. Introduction
Basement membranes (BM) are sheet-like, cell-adherent extracellular matrices (ECM) consisting
of an enmeshed polymer of laminins and collagen IV (Col IV) that are bound to nidogens, agrin,
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and perlecan [1]. They serve as both supportive cell substrata and solid-phase agonists, contributing
tissue organization, stability, and differentiation. Col IV is essential for basement membrane (BM)
stability [2], and laminins are critical to the general scaffolding of BM. Col IV is assembled by
extracellular oligomerization of triple-helical protomers and is covalently cross-linked by sulfilimine
(S=N) bond formation among the C-terminal non-collageneous 1 (NC1) domains that reinforce the
structural integrity of the Col IV networks [3]. Ablation of both Col IV subunit α1 and α2 in mice causes
lethality between E10.5 and E11.5 because of structural deficiencies in the BMs and eventual failure of
the integrity of Reichert’s membrane [2]. A dominant mutation of Col IV subunit chain α1 in mice
results in BM defects that affect the eye, kidney, and other tissues [4]. In humans, Col IV α1 mutation is
also associated with abnormalities of the anterior chamber of the eye, vascular leukoencephalopathy,
and hemorrhagic stroke [5–7]. Col IV α2 mutations in mice and humans also cause diseases similar to
those resulting from Col IV α1 mutations [8,9].
Peroxidasin (PXDN) is an ECM protein with peroxidase activity, which catalyzes formation of the
sulfilimine bond between a methionine sulfur and hydroxylysine nitrogen using hypohalous acids
in Col IV [10]. Loss or decrease of PXDN severely disrupts organogenesis in Drosophila, C. elegans,
and zebrafish by impairing basement integrity, leading to death at embryonic and larval stages
(Drosophila and C. elegans) or severely defective phenotypes, which consist of cardiac edema, decreased
eye size, and gross trunk patterning defects (zebrafish) [10–12]. The sulfilimine bond of Col IV is
considered to contribute to reinforcing the mechanical strength of BM and maintaining tissue integrity.
In mice and humans, much as in Col IV mutations, it can be postulated that PXDN mutations can cause
BM-linked diseases, more specifically, Col IV-associated diseases, such as porencephaly-1, intracerebral
hemorrhage, retinal arterial tortuosity, or anterior segment dysgenesis (ASD) [4,13]. Indeed, some
homozygous mutations in PXDN in humans cause severe inherited eye disorders, such as congenital
cataracts, corneal opacity, and developmental glaucoma because of ASD; other recessive mutations
in PXDN show a broader phenotype, including ASD, sclerocornea, microphthalmia, hypotonia,
and developmental delays [14,15]. Pxdn mutation-induced congenital eye diseases, such as ASD
and microphthalmia, were also revealed in recessive mutant mice induced by N-ethyl-N-nitrosourea
(ENU) [16]. The mutant mice highly resemble the manifestations in patients with PXDN mutations.
However, these pathogenic phenotypes are milder than expected from the studies of lower animals,
in which PXDN depletion causes embryonic and larval lethality or severely defective phenotypes.
In addition, it has not been established yet how inactivation of the PXDN gene affects tissue genesis
and organ development.
Here, we generated a knockout mouse model by deletion a sequence containing exon1 and its 5′
upstream sequences of the Pxdn gene using a CRISPR/Cas9-based genome editing system and analyzed
the phenotypes of homozygous/heterozygous mice. We found that the homozygous mice had no eyes
or extremely disorganized eye structures, whereas the heterozygous mice underwent development of
normal eyes with proper visual functions. Grossly, no external morphological defect was detected in
other organs. This study provides experimental evidence that PXDN is critical for eye development,
especially in constructing precise eye structures, and that PXDN is haplosufficient for eye structure
formation and normal visual function. This study also suggests that Pxdn knockout mice can be used
as a novel mouse model for anophthalmia and severely malformed microphthalmia.
2. Results
2.1. Generation of Pxdn Gene Knockout Mice
To identify the function of PXDN, we attempted to generate Pxdn gene knockout mice by means
of a CRISPR/Cas9 system using guide RNAs targeting the exon1 and its 5′ upstream sequences of
Pxdn (locus number, NC_000078.6) (Figure 1A). We performed genotyping analysis of founder mice
using tail-cut samples by PCR and Sanger sequencing. We found that some mice had variously altered
sequences compared with the normal Pxdn sequence. Among them, we selected founders that had
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deletion of the exon1 and its 5′ upstream sequences of the Pxdn gene (760 bps) (Figure 1B, red asterisk).
The Pxdn-deleted mutants were chosen on the basis of the analysis of hypothetical open reading frames
of the prospective transcript. The 760 bps-deleted mouse (female) was bred with C57BL/6N normal
strains and maintained as heterozygotes and homozygotes.
After a generation of progeny, the mutant mice were verified by PCR using genomic DNA isolated
from the lung tissues. When both primers located out of the deletion region were used, as expected,
wild-type (Pxdn+/+, WT) and (Pxdn−/−, KO) mice showed a single amplified DNA fragment (1096 bp
for WT, 336 bp for KO), whereas two DNA fragments were amplified because of two different alleles
of the Pxdn gene in heterozygous mice (Pxdn+/−) (Figure 1C). Next, we examined the inactivation of
the Pxdn gene at mRNA level in the KO mice. When PCR analysis was done using various primer
sets located in the region from 5′ UTR to 3′ UTR of PXDN mRNA, only WT and heterozygous mice
showed the expected PCR product amplified from the PXDN mRNA, and the KO mice showed no
amplified PCR product in any primer set (Figure 1D). These data show that deletion of the exon1 and
its 5′ upstream sequences of the Pxdn gene leads to complete inactivation of the Pxdn gene. To evaluate
Pxdn gene expression at the protein level, we generated a polyclonal antibody against a mouse PXDN
subdomain, which was an immunoglobulin (Ig)C2 (3–4) motif within the extracellular matrix motifs of
mouse PXDN. As shown in Figure 1E, PXDN was expressed in the lung tissues derived from WT and
heterozygous mice. Consistent with the RNA expression pattern, the PXDN protein was not detected
in the KO mice. Finally, we tested whether a known biochemical function of PXDN was lost upon
exon1 and its 5′ upstream sequences deletion of the Pxdn gene. PXDN is a matrix peroxidase enzyme
that crosslinks NC1 domains of Col IV by forming sulfilimine bonds [10]. Thus, we examined whether
PXDN deficiency leads to lack of sulfilimine bond formation in the KO mice. After the lung-tissue
lysate was digested by collagenase, the samples were immunoblotted using anti-Col IV α2 antibody.
Expectedly, the KO mouse samples showed no NC1 dimers, but instead increased NC1 monomers,
in contrast to WT or heterozygous mouse samples (Figure 1F). There was no change in dimer versus
monomer levels between the WT and heterozygous mouse samples, which was consistent with the
PXDN protein levels of the WT and heterozygous mice. Therefore, we concluded that the mutant
mice generated from deletion of exon1 and its 5′ upstream sequences of the Pxdn gene show complete
inactivation of the Pxdn gene, and that loss of PXDN leads to no sulfilimine crosslinking of the NC1
domains of Col IV.
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Figure 1. Construction of mice with deletion of the exon1 and its 5′ upstream sequences of the
peroxidasin (Pxdn) gene. (A) Genomic locus of mouse Pxdn gene on chromosome 12 and cutting
sites of sgRNAs. A total of 760 bps encompassing exon1 and its 5′ upstream sequences of the Pxdn
gene were deleted by the CRISPR/Cas9 system. (B) Genotyping of F0 mice (#1–#54). PCR was
performed using genomic DNA isolated from tail-cut samples and a primer pair, SF3 and SR3. The #52
mouse (asterisk) among deletion mutants had 760 bps deletion containing exon1 and its 5′ upstream
sequences of the Pxdn gene. (C) The genomic DNA isolated from the lung tissues of the progeny
mice was used for PCR analysis using primer pairs SF1 and SR2. (D) A schematic depiction of PXDN
with leucin-repeat-rich (LRR), immunoglobulin (Ig), peroxidase, and von-Willebrand factor type C
(vWFC) domains (upper panel). Inactivation of the Pxdn gene was verified by RT-PCR analyses (lower
panel). Total RNAs were isolated from the lung tissue of the mice and used for RT-PCR analysis using
specific primers that bind to different regions of the Pxdn gene: 5′ UTR-exon 19, exons 10–14 (IgC2
3–4 domain), exons 17–19 (peroxidase domain), and 3′ UTR region. GAPDH was used as a loading
control. (E) Immunoblot analysis of PXDN expression was done using the lung tissue of the mice
and anti-mouse PXDN polyclonal antibody. (F) Immunoblot analysis of non-collageneous 1 (NC1)
crosslinked dimer/un-crosslinked monomer levels of collagen IV (Col IV) using the lung tissue of the
mice. The tissue lysate was treated with collagenase prior to immunoblot analysis.
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2.2. External Morphological Defect Was Obvious in Eyes, but Not Other Organs in Pxdn-Null Mice
PXDN is expressed in endothelial cells, epithelial cells, and fibroblasts. Relatively high expression
of PXDN is observed in several human tissues such as the heart, spleen, kidney, and lung [17,18].
As PXDN stabilizes Col IV, a major component of BM, its deficiency in lower animals leads to lethality
because of disorganized tissue structures. However, when the Pxdn gene was inactivated in mice,
adult mice did not show any significant change in size and weight between the WT and mutant mice
(Figure 2A). In addition, these mice showed no changes in size and external morphology in most
organs, including the brain, heart, lung, spleen, kidney, and testis, except for the eyes (Figure 2B).
Small eyes were observed in the KO mice. In addition, as a minor change, change of hair color was
noticed and the tail color was white in two-thirds of the tip of the KO mice, which also had a white spot
at the ventral and dorsal region at a frequency of about 94.1%, as observed in the Pxdn mutant mice
(KTA048) with a premature stop codon [16]. The KO mice showed severe abnormalities in the external
appearance of the eyes compared to the WT and heterozygous mice (Figure 2C). They had completely
or almost closed eyelids, and some of them (#9-L, #93-L) had severe cataracts in the eyes, whereas the
heterozygous and WT mice born from the crossing had normal eyelids. Thus, we concluded that loss
of PXDN leads to severe external morphological defects of the eyes.
Figure 2. Deletion of the exon1 and its 5′ upstream sequences of the Pxdn gene caused congenital
malformation of eyes in mice. (A) Representative photograph of Pxdn(+/+) (WT), Pxdn(−/−) (KO),
and Pxdn(+/−) (heterozygous) mice at 9 weeks of age (left). Body weight of the WT (n = 3), KO
(n = 7), or heterozygous (n = 10) mice. (B) Comparison of the organs removed from the mice, which
were approximately 20 weeks old. (C) Representative external morphology of the eyes in the WT,
heterozygous, and KO mice. Compared with the WT (n = 34) or heterozygous mice (n = 115), completely
or almost closed eyelids were noted in the KO mice (n = 40).
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2.3. Extremely Disorganized Eye Structure Was Shown in Pxdn-Null Mice
To analyze histological abnormalities, we carried out hematoxylin and eosin staining (H&E) staining
using paraffin-embedded eye sections (Figure 3A). Histological analysis of the eye tissues of the KO mice
revealed extremely severe abnormalities. H&E staining displayed that lenses were completely missing
or remained in trace. Disorganization of retinal structure, such as retinal folds or rosette-like structures,
and retinal dysplasia were also observed. Furthermore, even eyeball formation was absent in the KO mouse
(#11-L). To confirm PXDN expression in the eye tissue of the mutant mice, we performed western blot
analysis. As shown Figure 3B, the KO mice did not express PXDN, in contrast to the WT and heterozygous
mice. When Col IV isoforms (α1 and α2), substrates of PXDN, were examined for gene expression by
RT-PCR analysis, the expression levels of both isoforms were reduced only in the eye tissues of the KO
mice with ocular developmental defects including missing lenses. Therefore, we concluded that PXDN is
important in organization of eyeball structure and lens development during eye development.
Figure 3. Histological analysis of Pxdn KO mice. (A) Representative histological data of the eye tissues
of the WT, heterozygous, or KO mice (13–15 weeks old). Paraffin-embedded eye sections were stained
with hematoxylin and eosin staining (H&E). The eye tissues of heterozygous mice (n = 10, male = 5,
female = 5) displayed normal anterior segments similar to that of the WT mice (n = 6, male = 3, female =
3), whereas the eye tissue of the KO mice (n = 6, male = 4, female = 2) exhibited extremely disorganized
eye structures or no eyeball structure. Scale bar: 200 µm. (B) Western blot analysis of PXDN expression
was done using the eye tissue of the mice. β-actin was used as a loading control. (C) RT-PCR analyses
of PXDN and Col IV α1 and α2 expression in the eye tissues of the WT, KO, and heterozygous mice.
A total of 28 cycles for PXDN and Col IV α1 and 33 cycles for Col IV α2 were carried out for the RT-PCR
analysis. GAPDH was used as a control.
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2.4. The Pxdn Gene Is Haplosufficient for Visual Function
There were no differences observed in external morphology, PXDN expression, or Col IV
crosslinking level between the WT and heterozygous mice, although deletion of double alleles of the
Pxdn gene led to no eyeball structures or extremely disorganized eyes. Thus, we were interested in
whether a single-allele Pxdn gene is sufficient for eye function. To evaluate visual function, we measured
visual acuities and intraocular pressure (IOP) for the WT and heterozygous mice (13–15 weeks old)
using optokinetic nystagmus and tonometry. There was no difference in visual acuity (Figure 4A)
or IOP (Figure 4B) between the WT and heterozygous mice. We also used fundus biomicroscopy to
analyze the phenotype of retinas, including the retina, optic nerve, and distribution of retinal blood
vessels. We found that both the WT and the heterozygous mice showed a normal retinal phenotype
(Figure 4C). By means of optical coherence tomography (OCT), we confirmed normal structure of the
cornea, lens, and retina in both the WT and heterozygous mice (Figure 4D). There was no difference in
inner plexiform layer (IPL), inner nuclear layer (INL), outer nuclear layer (ONL), or retinal pigment
epithelium (RPE) retinal ratio between the two groups according to OCT retinal-layer depth analysis
of the WT and heterozygous mice (Figure 4E). The electrical signal stage by stage-light stimulation of
rod and cone cells and their response time by means of electroretinography (ERG) in scotopic/photopic
condition also did not show any significant differences between the WT and heterozygous mice
(Figure 4F,G). Such results indicate that the heterozygous mice had no defect in behavior, morphology,
or function in visual acuity compared to the WT mice. Therefore, we concluded that the Pxdn gene is
haplosufficient for visual function.
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Figure 4. Visual test of the WT and heterozygous mice. (A) Visual acuity was measured by optokinetic
nystagmus. (B) Mouse intraocular pressure (IOP) was measured using tonometry equipment. NS,
not significant. (C) Fundus photography was used to compare any changes in retina, optic nerve, or
retinal vessels pattern between the WT and heterozygous mice. Both groups showed a normal retinal
phenotype with the radial pattern of arterioles and venules. (D) Representative optical coherence
tomography (OCT) cross-section images including cornea, lens, and retina by horizontal meridian of
the WT and heterozygous mice. (E) The retinal layer and boundary identifications: inner plexiform
layer (IPL), inner nuclear layer (INL), and outer nuclear layer (ONL). (F) Evaluation of visual function
in the mice following electroretinography (ERG) recording. ERG recordings of photopic ERGs and
scotopic ERGs from the WT and heterozygous mice were performed. Dark-adapted and light-adapted
ERGs were elicited by eight or six different stimulus intensities in rod and cone cells, respectively.
ERG a-waves are shown in amplitude of dark-adapted and light-adapted conditions (left). ERG b-waves
are shown in amplitude of dark-adapted and light-adapted conditions (right). (G) The response time
of light sensitivity of retina (n = 6/WT and n = 10/heterozygote).
3. Discussion
Because PXDN is known to catalyze the formation of the sulfilimine crosslink that stabilizes
the Col IV network for mammalian tissue genesis [19], we suspected there would be embryonic
lethality or severe impairment of development in Pxdn-null mice. However, unlike our speculation,
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the Pxdn KO mice did not show any apparent external morphological changes compared to those of
the wild-type mice except for the abnormal ocular phenotypes, anophthalmia, and severely malformed
microphthalmia. Previously, it had been reported that the ENU-induced Pxdn mutation that has a
premature stop codon (Cys1272X) leads to severe anterior segment dysgenesis and microphthalmia [16].
In humans, the patients with several inherited mutations of the PXDN gene also display eye disorders at
various levels [14,15]. Such a phenotype shown by PXDN mutations in humans and mice was displayed
in the Pxdn KO mice. In the Pxdn KO mice, deletion of exon1 and its 5′ upstream sequences of the Pxdn
gene resulted in complete gene inactivation by showing no mRNA/protein expression of PXDN in
the tissues. On the other hand, the Pxdn mutation with the premature stop codon (Cys1272X) was
predicted to cause loss of function of peroxidase enzyme activity with the loss of the von-Willebrand
factor type C (vWFC) domain [16]. In their data, an immunofluorescence study showed that PXDN
is expressed in the lens and the inner neuroblast layer of mutant eyes at E17.5 with an expression
pattern similar to that of wild types. The peroxidase inhibitor phloroglucinol inhibits formation of
sulfilimine crosslinks by PXDN at the cellular level [10], and mutagenesis studies have also revealed
that peroxidase activity is required for sulfilimine-bond formation by PXDN [20,21]. On the other
hand, it cannot be excluded that ECM motifs can have their own function. Thus, it should be clarified
in the future whether this point-mutated mouse expresses the truncated form of PXDN with loss of
peroxidase activity and vWFC domain, and whether N-terminal ECM motifs can complement PXDN
deficiency at some levels in mice. In this study, although Pxdn-null mice showed severely defective eye
phenotypes, the heterozygous mice with only a single intact allele did not show any defect in structure
and visual function of eyes. Thus, we clearly showed that one allele of the Pxdn gene is sufficient for
eye structure formation and visual function.
Because a number of ophthalmological differences and sequence variants between C57BL/6J and
C57BL/6N strains were identified from the comparative phenotypic and genomic sequence analysis [22],
it cannot be ruled out that the different genetic backgrounds for the C1272X mutants (C57BL/6J) and
the KO mice (C57BL/6N) may contribute to the differences in phenotype. However, the comparison of
the general visual functions of the two strains shows only reduced vision in C57BL/6N mice compared
with C57BL/6J mice, not reflected relative to differences in lens opacities in both strains. Thus, severe
ocular malformation by biallelic deletion of Pxdn is not likely strain-dependent, but further studies are
needed in future for clarification on this point.
Like the mutant mice with this premature stop codon (Cys1272X), the Pxdn KO mice had a white
spot at the ventral and/or dorsal region, and their tail color was white in two-thirds of the tip [16].
The previous report noted that this phenotype is reminiscent of some mutations affecting migration of
neural crest cells, which also affects eye development [16,23,24]. Thus, it is interesting to figure out
how Pxdn gene function is correlated with neural crest cell migration.
The lens capsule is a modified BM, which is important for structure, biomechanics, and maintenance
of the lens cell phenotype [25]. Some core structural molecules, including Col IV, laminin, and nidogen,
provide protective and signaling roles for the mature lens. Col IV point mutants act as dominant
negative molecules and affect synthesis and secretion of Col IV or the function of the Col IV network,
which leads to defects of the kidneys, esophagus, aorta, and eyes [4]. Therefore, BM defects can lead to
damage to cell and tissues, developmental defects, and diseases [19]. The decrease of Col IV expression
level in the eye tissue of the Pxdn KO mice compared with that of the WT mice may be because of ocular
developmental defects including missing lenses, as Col IV is highly expressed in lens capsules [26].
From this study, PXDN deficiency is presumed to be associated with developmental disability in eyes,
as they lack the stability of the Col IV network because of the deficiency of sulfilimine crosslinks.
The defect in eye phenotype of Col IV mutant mice, such as iris/corneal adhesion, is similar to that of
the Pxdn mutant mice [16], and the Pxdn KO mice showed highly disorganized eye structure or no
eyeballs. Therefore, the sulfilimine crosslinks in Col IV may be very important in the development of
eye tissue, which requires a complex, precise structure for precise functioning of the eyes. In addition,
this fact suggests the importance of the BM integrity generated by PXDN, which is responsible for
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Col IV network stability. However, it is notable that Pxdn gene inactivation by deletion of exon1 and
its 5′ upstream sequences leads to no apparent developmental defect in kidney, esophagus, or aorta,
which is different from the defects of Col IV mutant mice [4]. A recent study using Pxdn KO mice
generated by exon 9 deletion also showed no alteration of BM structure in the renal glomeruli or
tubules, but reported a finding that reduced Col IV sulfilimine crosslinks reduced renal tubular BM
stiffness [27]. This finding corresponds with our finding suggesting the importance of BM integrity
driven by PXDN.
Considering that the sulfilimine bond is presumed to provide the mechanical strength for the
Col IV network, it is still questionable as to why it is important in the development of the eyes.
Anophthalmia, the most severe phenotype, is associated with mutations of the Rax, Sox2, Lhx2, BMP-4,
and BMP7 genes [28]. Complete inactivation of these genes also displays embryonic lethality because
of broad impacts on development. Pax-6 homozygous mutants, the classical model for anophthalmia in
the mouse, do not develop eyes, but die perinatally because of other developmental defects, including
those of the central nervous system [29,30]. In the future, it will be interesting to address why the
contribution of PXDN in tissue genesis of mice is markedly significant only for the eyes, but not for
other organs, such as the kidneys and vessels.
From this study, we can suggest that the Pxdn gene is haploid sufficient for normal eye development
and visual function, providing evidence that PXDN is essential for eyeball development. It will be also
interesting to investigate in the future whether PXDN is correlated with the pathogenesis of glaucoma
and cataract in adult eyes after normal eye development.
4. Materials and Methods
4.1. CRISPR/Cas9 for Pxdn Gene Knockout
We purchased SpCas9 protein and sgRNAs to generate Pxdn knockout mice from Macrogen, Inc.
(Seoul, Korea). To knock out the Pxdn gene (NC_000078.6), we designed two sgRNAs (1 (5′ UTR
gR3), GTCGCTAGGTTCAGACACCAAGG; 2 (intron1-2-gR2), CTCAACTTTCTCTCCACTCGGGG)
to target the exon1 and its 5′ upstream sequences of the Pxdn gene and validated them
using the T7E1 in vitro cleavage reaction of template DNAs, which were amplified by
PCR (F1:5′-TGTGGGAACAGTGGTGGGCA-3′ and R1: 5′-GTGAACAGCAGCGGAGGAG-3′, F2:
5′-CAGGGGTACTGGTTTGGAGA-3′ and R2: 5′-CCAAGCAAAGAAAAAGCTCCT-3′). Briefly,
the amplified template DNA was incubated for 90 min at 37 ◦C with Cas9 protein (20 nM) and sgRNA
(40 nM) in 1×NEB 3 buffer. Reactions were stopped with 6× stop solution containing 30% glycerol, 1.2%
SDS, and 100 mM EDTA. Cleavage activity was confirmed by electrophoresis of the reaction mixture.
4.2. Generation of Pxdn Gene Knockout Mice
Pxdn knockout mice were generated by Macrogen, Inc., and were interbred and maintained in a
pathogen-free condition at Macrogen, Inc. (Seoul, Korea). All animal experiments were performed
in accordance with the Korean Food and Drug Administration (KFDA) guidelines. Protocols were
reviewed and approved by the Institutional Animal Care and Use Committees (IACUC) of Macrogen,
Inc. (MS-2016-01(5 October 2016)). All manipulations were conducted with the Institutional Animal
Care and Use Committee approval. Briefly, pregnant mare serum gonadotropin (PMSG) and human
chorionic gonadotropin (hCG) were injected into C57BL/6N female mice. After 48 h, these female
mice were mated with C57BL/6N stud male mice. Next day, virginal plug-checked female mice were
sacrificed and fertilized embryos were harvested. The mixture of sgRNA and SpCas9 protein was
microinjected into one-cell embryos, and microinjected embryos were incubated at 37 ◦C for 1–2 h.
Then, 14 to 16 injected one-cell-stage embryos were transplanted into oviducts of pseudopregnant
recipient mice (ICR). After F0 mice were born, genotyping was done by direct PCR and sequencing
methods using tail-cut samples (SF3 primer, 5′-TGGCAGAACTGGGTAACTCC-3′; and SR3 primer,
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5′-CAATCTCCCCCAGAGGAAGT-3′). Among of the founders with altered sequences, we selected F0
mice with deletion of exon1 and its 5′ upstream sequences of Pxdn.
4.3. Genotyping
Genomic DNA was isolated from the lung tissues of each mouse using an MGmed tissue kit
(MGmed, Seoul, Korea). Genotyping was done by PCR amplification using the following primers:
SF1, 5′-AAGCAGAATCAGGGATCCAA-3′; and SR2, 5′-AGCCGATGGGAGTACACTTG-3′. The PCR
products were visualized by agarose gel electrophoresis; a 1096 bp fragment was amplified in the
wild-type mice, both 1096 bp and 336 bp fragments in the heterozygous mice, and a 336 bp fragment in
Pxdn-null mice.
4.4. RT-PCR Analysis
Expression of PXDN in the tissues was confirmed by RT-PCR analysis. Total RNA was extracted
from the tissues by Trizol reagent (Invitrogen, Carlsbad, CA, USA). We performed cDNA synthesis
using the SuperScript synthesis system for RT-PCR (Enzynomics, Daejeon, Korea) according to the
manufacturer’s instructions. The primer sets used for PXDN were as follows: for 5′ UTR-exon 19,
forward, 5′-GACCGGAGGGCTCAGTTG-3′ and reverse 5′-ACACGGGTGATGTTGTCTGA-3′; for
exon 10–14 (IgC2 3-4 domain), forward 5′-CGCGCGGCAGCCATATGGCCCTTCTCAGTTCACT-3′
and reverse 5′-GTTAGCAGCCGGATCCTCAATTCACACTGAGTACCATGCT-3′; for exon
17–19 (peroxidase domain), forward 5′-GGCTGTATGGCTCGACTCTC-3′and reverse
5′-ACACGGGTGATGTTGTCTGA-3′; for 3′ UTR, forward 5′-GGCTAGGGAGGAAGACCTCA-3′
and reverse 5′-CCTGGGCAATGAGGCTGTAA-3′; for GAPDH, forward
5′-CATGACCACAGTCCATGCCATCACT-3′ and reverse 5′-TGAGGTCCACCACCCTGTTGCTGTA-3′.
The following primers were used to measure the mRNA expression level of Col IV: forward
5′-GCCAAGTGTGCATGAGAAGA-3′ and reverse 5′-AGCGGGGTGTGTTAGTTACG-3′ for Col IV α1,
forward 5′-CCGATTCCACGAGCCCCTT-3′ and reverse 5′-CTCCTTTCTCCGGGTAGCAC-3′ for Col
IV α2. PCR amplification for PXDN mRNA expression was done under the following conditions:
95 ◦C for 1 min, followed by 28–33 cycles of 1 min at 95 ◦C, 1 min at 56–64 ◦C, and 1–4 min at 72 ◦C.
The PCR product was loaded in 1–2% agarose gel mixed with SYBR safe dye (Invitrogen).
4.5. Preparation of Anti-Mouse PXDN Antibody
The recombinant peroxidasin IgC2 (3–4) subdomain (amino acids 428–609) of mouse PXDN
was prepared for antibody production. A 546 bp DNA fragment encoding amino acids spanning
from Ala (428) to Asn (609) of mouse PXDN was amplified by PCR using mouse lung cDNA,
Pfu polymerase, and primers (forward: 5′-CGCGCGGCAGCCATATGGCCCTTCTCAGTTCACT-3′,
reverse: 5′-GTTAGCAGCCGGATCCTCAATTCACACTGAGTACCATGCT-3′) and subcloned between
the NdeI and BamHI sites of pET-15b (Novagen, Madison, WI, USA). Then, the recombinant protein
was expressed in E. coli BL21 (DE3) and purified from the cell pellet as described previously [31].
Polyclonal antibody was raised in rabbits against the purified recombinant protein (Abfrontier,
Seoul, Korea).
4.6. Western Blot Analysis
For protein preparation, the tissues were dissected and lysed using lysis buffer (50 mM Tris (pH
8.0), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM Na3VO4, 50 mM
NaF, 1 mM EDTA, 1 mM EGTA, 2 mM PMSF, 1 µg/mL pepstatin, and protease inhibitor mix (Roche,
Basel, Switzerland)). The lysate was centrifuged at 14,000 rpm for 30 min, and then the supernatant
was subjected to 8% SDS-PAGE. Separated proteins were transferred to a nitrocellulose membrane,
and the membrane was blocked with 5% skim milk. Blots were incubated with polyclonal anti-mouse
PXDN antibodies raised against recombinant IgC2 (3–4) subdomain, and then with horseradish
peroxidase (HRP)-conjugated secondary antibodies. GAPDH or β-actin was used for a loading control.
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We visualized the immunoreactive bands using a chemiluminescent substrate (ECL kit) (Amersham,
Amersham, United Kingdom).
4.7. Detection of NC1 Sulfilimine Crosslink
We assessed the level of NC1 domain sulfilimine crosslinking in Col IV according to a procedure
reported previously [32]. Briefly, the lung tissues were lysed in hypotonic lysis buffer (10 mM CaCl2,
50 mM HEPES, pH 7.4, 0.1 mM benzamininde hydrochloride, 25 mM 6-aminocaproic acid, and 1 mM
PMSF). The tissue lysate was digested with 0.5 mg/mL collagenase (Gibco) at 37 ◦C for 18 h and then
subjected to SDS-PAGE under reducing conditions followed by western blotting. Crosslinked dimeric
and un-crosslinked monomeric NC1 domains were detected with anti-Col IVα2 antibody (ChondrexInc,
Redmond, WA, USA).
4.8. Hematoxylin and Eosin Staining
For the histological examination, the eye specimen was fixed with 4% Davidson’s solution for
24 h with gentle shaking. Fixed samples were paraffin-embedded and cut into 5 µm sections using a
microtome (RM2335, Leica, Wetzlar, Germany). Hematoxylin and eosin staining (H&E) was done after
a day of sectioning. For H&E staining, paraffin sections were deparaffinized and then hydrated in a
descending grade of ethanol. Next, we stained sections with 0.1% Mayer’s hematoxylin for 10 min
and 0.5% eosin in 95% EtOH. After staining with hematoxylin and eosin, the washing steps were
immediately and sequentially done as follows: dipped in distilled water until eosin stopped streaking,
dipped in 50% EtOH 10 times, dipped in 70% EtOH 10 times, and incubated in 95% EtOH for 30 s and
100% EtOH for 1 min. Then, samples were covered with mount solution (6769007, Thermo Scientific,
Waltham, MA, USA) and examined under the light microscope (BX43, OLYMPUS, Shinjuku, Japan).
4.9. Optokinetic Nystagmus (OKN)
All mice for visual function tests were in accordance with protocols approved by the Institutional
Animal Care and Use Committee (IACUC: 2018-0145) of Yonsei University. All animals were handled
according to the principles of the Association for Research in Vision and Ophthalmology statement.
We assessed spatial frequency thresholds (i.e., visual acuity) by optokinetic nystagmus (OKN) using
a virtual optokinetic system (OptoMotry, Cerebral Mechanics, Medicine Hat, Alberta, Canada).
A video camera located on the ceiling of the device recorded the images and sent them to the connected
computer. The clockwise movement was to track the movement of the left eye, and the counterclockwise
movement tracked the reaction of the right eye of the mouse. The experimenter judged whether the
head and body of the mouse were tracking according to the direction in which the drift grid was
rotating. If the presence of the tracking was unclear or absent, the retry was resumed, ignoring large
repositioning and grooming movements. The maximum spatial frequency capable of driving head
tracking was determined.
4.10. Tonometry
We anesthetized mice with an intraperitoneal injection of xylazine (10 mg/kg; Rompun,
Bayer Animal Health, Leverkusen, Germany) and zolazepam and tiletamine (30 mg/kg; Zoletil 50,
Vibrac, Carros, France). Intraocular pressure (IOP) was measured using a rebound tonometer (Icare
TONOLAB tonometer, Colonial Medical Supply, Franconia, NH, USA). IOP measurements were
taken according to the manufacturer’s instructions. One trial result was given after six consecutive
measurements, and the mean of consecutive trials was used for analyses.
4.11. Optical Coherence Tomography (OCT)
We anesthetized mice with an intraperitoneal injection of xylazine (10 mg/kg; Rompun, Bayer
Animal Health) and zolazepam and tiletamine (30 mg/kg; Zoletil 50, Vibrac, Carros, France). The pupils
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were dilated with 0.5% tropicamide and 0.5% phenylephrine mixed eyedrop (Mydrin-P, Santen
Pharmaceutical Co, Ltd., Osaka, Japan). Optical coherence tomography (OCT) scans were taken using
the Eyemera OCT (IISCIENCE, Busan, Korea). The cornea was lubricated with hypromellose 2.5%
(Goniovisc, Hub Pharmaceuticals LCC, Roncho Cucamonga, CA, USA). After placing the mouse in
front of the OCT lens and focusing on the retina, fundus photography and OCT scan were performed.
Retinal thickness was measured using InSight-Animal OCT Segmentation Software (Phoenix Research
Labs, Pleasonton, CA, USA). Each scan for cornea, lens, and retina centered on the optic nerve
was obtained.
4.12. Electroretinography (ERG)
We performed ERG analysis using Micron Ganzfeld ERG (Phoenix Research Labs, Pleasanton,
CA, USA). Mice were dark-adapted at least 12 h before the experiment for scotopic testing (rod-cell
response). After anesthesia, the pupil was dilated as previously described. Once the pupil was fully
dilated, we applied hypromellose 2.5% (Goniovisc) and inserted the electrodes. ERG was recorded
as Ganzfeld ERG according to the standard protocol of the manual instruments. Scotopic ERG was
obtained with increasing flash intensity in the range of −1.7 log cd/s/m2 to 1.9 log cd/s/m2. Mice were
light-adapted for 15 min prior to the cone-cell response experiment. Photopic ERG was done with
a flash intensity in the range of −0.5 log cd/s/m2 to 4.1 log cd/s/m2. A total of 10 responses to light
stimuli were averaged. The implicit times of a-wave (as a measure of photoreceptor function), b-wave
(as a measure of bipolar cell function), amplitude, and rod- and cone-cell response were determined.
4.13. Data and Statistical Analysis
Data were presented as means ± SEM of representative experiments. All the in vivo visual
experiments were performed at least six times. Student’s t-test was used to calculate statistical
difference between the two groups.
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